The Asteroid trial Ablative Stereotactic radiotherapy With Durvalumad (MEDI4736). An open label randomized phase II trial with durvalumab following stereotactic body radiotherapy (SBRT) in painets with T1-2 N0M0 Non- small cell lung cancer (NSCLC)
Principal investigator: Anu Anttonen
Trial site: HUS Comprehensive Cancer Center
